Proper progression through the cell cycle is dependent on an ordered sequence of events, including DNA replication, chromosome condensation and cytokinesis. In eukaryotic cells, waves of cyclin-dependent kinase (CDK) activity coordinate these events [1] [2] [3] . During the G1/S transition, cyclin D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 complexes are active 4 . The activities of the cyclin-CDK complexes are further refined by a number of CDK inhibitors (CKIs) such as p16, which simultaneously inhibits multiple CDKs and whose gene (CDKN2A) is a frequent target of deletion in cancer 5, 6 . These processes establish proper cell cycle control and the maintenance of genomic integrity.
Orderly and unidirectional progression from one cell cycle phase to the next is accomplished by a cascade of tightly regulated ubiquitination events targeting the cyclins 2 . Two families of ubiquitin ligases, the Skp/cullin/F-box-containing (SCF) complexes and the anaphase-promoting complexes (APCs), ubiquitinate and target specific cyclins for destruction 7, 8 . For the cyclins involved in the G1/S transition, cullin-RING ligases (CRLs)-such as the SCF or SCFlike complexes-execute this process 9 . The FBX4-containing SCF complex (SCF4) targets cyclin D for proteolysis, and the FBXW7-containing SCF complex (SCF7) targets cyclin E for degradation 10, 11 . It has been known for decades that cyclin levels during the G1/S transition are tightly coordinated, but how the stabilities of cyclin D and cyclin E are tied together is a fundamentally important question that has remained unanswered 12 .
PARK2 genetic alterations are common across many human cancers as well as in hereditary Parkinson's disease [13] [14] [15] . In cancer, the PARK2 gene is mutated and/or deleted, with copy number loss being the primary mode of alteration 13, 16 . One approach to determine the function of a somatic genetic alteration is to identify alterations that are mutually exclusive with it, as patterns of genetic alteration can be used to infer and inform biological pathways and function [17] [18] [19] . We therefore examined patterns of PARK2 deletion across 4,934 tumors spanning 11 cancer types. Deletions of PARK2 were the fourth most significant deletion among 70 significantly recurrent regions of deletion across the entire data set, and the focus (minimal commonly deleted region) of these deletions included no genes other than PARK2 (false discovery rate (FDR)-corrected q value; Fig. 1a) , identifying PARK2 as the driver of this region of loss. Focal deletions of PARK2 occurred in 11% of tumors across all lineages and loss of the entire chromosome arm occurred in 19% of samples, resulting in an overall 30% rate of loss. Deletions of PARK2 were most common in serous ovarian, bladder and breast carcinomas (62%, 38% and 32% deletion rates, respectively; Supplementary Fig. 1 ). These pan-cancer data indicate that PARK2 is one of the most frequently deleted genes in human cancer.
Focal deletions involving PARK2 were significantly anticorrelated with focal amplifications of five known oncogenes (CCND1, CCNE1, Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins CDK4, BCL2L1 and PAX8) and one known tumor suppressor (BRCA1; Fig. 1b and Supplementary Tables 1 and 2) . We identified these instances of anticorrelation after rigorously controlling for tumor lineage and for overall levels of genomic disruption; both of these factors can confound correlation analyses (Online Methods) 20, 21 . PARK2 deletions anticorrelated with more recurrent somatic copy number alterations (SCNAs) than deletion of any other large gene, suggesting that loss of PARK2 is selected for because of its contribution to tumorigenic potential rather than occurring passively (Fig. 1c) . Many of the largest genes in the genome tend to be recurrently deleted, with 20 of the top 70 most frequently deleted regions containing 1 of the 100 largest genes in the genome 21 . Many deletions encompassing large genes might arise owing to processes that occur during cancer evolution, rather than contributing to oncogenesis 13, 22 . In this case, we expect that SCNAs affecting regions containing large genes would show few anticorrelations with other regions of significant alteration. Among the 34 significant regions with known driver genes and 20 significant regions with large genes, driver genes exhibited significantly more anticorrelations with other regions (median of 1 and 4 anticorrelations for large genes and driver genes, respectively; MWW = 0.0002; Fig. 1c ) 21 . However, PARK2 deletion was an exception to this trend, with only three other significant deletions having more interactions than PARK2-STK11, NF1 and BRCA1-all known tumor suppressors that often undergo copy number loss. These findings strongly support a tumor suppressive role for PARK2 in human tumors and suggest that PARK2 deletions might serve some of the same functions as the alterations with which they anticorrelate.
The genetic relationship between PARK2, CCND1 (cyclin D1), CCNE1 (cyclin E1) and CDK4 is particularly intriguing. Cyclin D1, cyclin E1 and CDK4 all control G1/S progression and are all encoded by oncogenes that are frequently amplified in many different types of human malignancy 13, [23] [24] [25] . One possibility is that, if PARK2 loss serves a similar function as copy gains of these cyclin genes and CDK4, this redundancy should lead to anticorrelation of these events in primary tumors 19, 26, 27 . Our analysis, which used a lineage control to detect anticorrelations between peak regions of significance, found strong anticorrelation between the presence of amplifications at the loci containing CCNE1 and CCND1, as expected, as well as between the presence of amplification of either of these regions and PARK2 loss (Fig. 1b and Supplementary Table 2) . The anticorrelations between PARK2 loss and CCND1, CCNE1 and CDK4 gain were highly statistically significant and were much stronger than would be expected in the absence of selective pressure (Fig. 1d) . These relationships were especially strong in tumor lineages where CCND1, CCNE1 or CDK4 amplification is frequent and is known to have an oncogenic role (i.e., breast and ovarian lineages). Such a pattern of mutual exclusivity is consistent with PARK2, cyclin D1, cyclin E1 and CDK4 functioning in a common pathway 19, 26, 27 .
Although our genetic data implicate a functional relationship between PARK2 and cyclin D1, cyclin E1 and CDK4, the molecular mechanisms underlying this relationship are unclear. To characterize the effects of PARK2 inactivation in cells, we knocked down PARK2 in three different cell lines with intact PARK2 expression and examined the effects on cell proliferation. In all lines tested, depletion of PARK2 resulted in increased proliferation (Fig. 2a,b) . Accordingly, inactivation of PARK2 resulted in significantly greater numbers of cells undergoing DNA synthesis (determined through analysis of 5-bromo-2′-deoxyuridine (BrdU) incorporation) ( l e t t e r s npg l e t t e r s and Supplementary Fig. 2 ). We next measured the amount of cyclin D1-CDK complex-dependent RB phosphorylation activity after PARK2 knockdown. We observed that enhanced cell cycle progression after PARK2 depletion was accompanied by an increase in cyclin D-CDK complex-mediated RB phosphorylation activity (Fig. 2d) . To study global changes in the transcriptome resulting from PARK2 depletion, we performed expression array analyses with two cell lines (SF539 and SNB19) ( Supplementary Fig. 3 and Supplementary Table 3) . Pathway analysis of genes with altered expression showed consistent enrichment of the transcriptional programs governing cell growth and cell cycle control ( Supplementary   Fig. 4 and Supplementary Table 4) . Depletion of PARK2 resulted in the consistent upregulation of genes associated with cell growth and proliferation (Supplementary Tables 3 and 4) . PARK2 is an E3 ubiquitin ligase that targets proteins for destruction, and mutations in the PARK2 gene in both cancer and Parkinson's disease inactivate this function 15, 16, [28] [29] [30] [31] [32] . Given this observation and our genetic data implicating PARK2 in cyclin biology ( Fig. 1) , we examined how inactivation of PARK2 affected the protein levels of npg l e t t e r s key components of the cell cycle machinery (Fig. 3a) . Knockdown of PARK2 resulted in a substantial accumulation of the cyclin D1 and cyclin E1 proteins but not of other cell cycle effectors. This accumulation of cyclin D1 and cyclin E1 was not due to increased transcription of the corresponding genes (Supplementary Fig. 5 ). We also found that the protein levels of cyclin D2 and cyclin D3 were higher after PARK2 knockdown (Supplementary Fig. 6 ). Furthermore, overexpression of the PARK2 E3 ubiquitin ligase resulted in a coordinate decrease in the npg l e t t e r s levels of cyclin D1 and cyclin E1 but not in the levels of cyclin A and cyclin B (Fig. 3b) . Interestingly, PARK2 mutations that we previously identified in cancer 16 abrogated the ability of the E3 ligase to degrade both cyclin D1 and cyclin E1. In combination, these data demonstrate that PARK2 is required for the normal regulation of cyclin D and cyclin E levels and that cancer-specific mutations affecting PARK2 abrogate its ability to target these cyclins for degradation. We next examined the molecular details of how PARK2 controls the amount of cyclin D1 protein. PARK2-mediated degradation of cyclin D1 was dependent on the proteasome, as it could be reversed using the proteasome inhibitor MG132 (ref. 33) (Fig. 4a) . Moreover, the Thr286Ala mutant of cyclin D1 was resistant to degradation by PARK2 (Fig. 4b) . As phosphorylation of cyclin D1 at Thr286 is required for its ubiquitin-mediated degradation by SCF4, these data show that PARK2-mediated destruction of cyclin D1 is dependent on this process 34, 35 . PARK2 mutations that we previously identified in cancer 16 abrogated E3 ligase activity (Fig. 4c) . We found that wild-type PARK2 directly bound to and ubiquitinated cyclin D1, whereas cancer-specific mutations affecting PARK2 abrogated its ability to do both (Fig. 4d,e) . PARK2 also interacted with cyclin D2 and cyclin D3 (Supplementary Fig. 7) . Overexpression of PARK2 in cells lacking PARK2 resulted in a significant decrease in the half-life of cyclin D1, whereas knockdown of PARK2 in cells that expressed the protein resulted in an increase in cyclin D1 half-life (Fig. 4f) .
Cyclins are ubiquitinated and marked for proteasome-dependent degradation by CRL complexes 36 . Although FBX4 is a known mediator of cyclin D destruction, its activity does not fully account for all cyclin D regulation [37] [38] [39] . We next sought to determine whether PARK2 acts within the context of an SCF-related CRL complex. We found that PARK2 is a component of a new FBX4-containing SCF-like ubiquitin ligase complex (Fig. 5a) . The PARK2-containing CRL complex includes the E3 ligase FBX4, the scaffold protein cullin-1 (CUL-1) and αβ-crystallin but not SKP1 or RBX1 (hereafter referred to as PCF4; Fig. 5a ). The PCF4 complex bears similarity l e t t e r s to SCF4, and this complex also ubiquitinates and targets cyclin D1 for destruction in a phosphorylation-dependent manner (Thr286) 35 .
We verified the interaction of PARK2 and CRL components by systematically expressing these proteins in combination using baculoviruses and characterizing their associations (Fig. 5b) . As expected, PARK2 interacted with FBX4, CUL-1 and αβ-crystallin but not with SKP1 or RBX1. These data indicate that PARK2 is a component of a new SCF-like ubiquitin complex that targets cyclin D1 for destruction. Because both PARK2 and FBX4 can bind to and ubiquitinate cyclin D, we wondered what the functional relationship was between these two E3 ligases. To address this question, we knocked down FBX4, PARK2 or both genes simultaneously and characterized the resultant effects on cyclin D1 protein levels. Loss of either FBX4 or PARK2 alone resulted in accumulation of cyclin D1 protein (Fig. 5c) . Moderate loss of both ubiquitin E3 ligases resulted in a synergistic effect, leading to dramatic accumulation of cyclin D1. When recombinant PARK2 and FBX4 were combined in vitro, the E3 ligases clearly synergized to ubiquitinate cyclin D1 (Fig. 5d) . Taken together, these data show that PARK2 and FBX4 work together to regulate cyclin D.
Along with regulating cyclin D levels during the G1/S transition, PARK2 also targets cyclin E for degradation. Depletion of PARK2 with small interfering RNA (siRNA) resulted in accumulation of cyclin E1 protein (Fig. 3a) . Overexpression of wild-type but not mutant PARK2 resulted in a decrease in cyclin E1 levels but not in the levels of cyclin A or cyclin B (Fig. 3b) . Using in vitro ubiquitination assays, we found that, as with cyclin D1, wild-type PARK2 ubiquitinated cyclin E1, but cancer-specific mutations affecting PARK2 abrogated the ability of the E3 ligase to do so (Fig. 6a) . Furthermore, wild-type PARK2 can bind to cyclin E1, whereas PARK2 mutations found in cancer disrupt this association 16, 40 (Fig. 6b) . Using immunoprecipitation, we found that PARK2 binds cyclin E1 and FBXW7 and is part of an SCF-like ubiquitin complex that contains both FBXW7 and CUL-1 but not SKP1 (hereafter called PCF7) [41] [42] [43] (Fig. 6b,c) . As with cyclin D, mutations affecting PARK2 disrupted its ability to bind to components of this CRL complex (Fig. 6c) . We validated the association of PARK2 and FBXW7 by expressing both proteins using baculoviruses and demonstrated that the two proteins precipitate together (Fig. 6d) . We then knocked down PARK2 and FBXW7 individually or simultaneously, as with FBX4 (Fig. 6e) . Depletion of either protein increased cyclin E1 levels. However, in contrast to results with FBX4 depletion, knockdown of PARK2 and FBXW7 together had an additive effect on cyclin E1 degradation, as least in the system we employed. Thus, as in the PCF4 complex, PARK2 and FBXW7 cooperate in the PCF7 complex to ubiquitinate cyclin E, albeit with different kinetics. Nevertheless, as part of PCF complexes, PARK2 coordinates the levels of multiple G1/S cyclins and, in essence, acts analogously to p16, although at the level of cyclin stability (Fig. 6f) .
Colorectal cancers (CRCs) can harbor substantial numbers of FBXW7 mutations and PARK2 deletions. Interestingly, most tumors contained an alteration in either FBXW7 or PARK2, although a small set of tumors did have alterations in both genes (Supplementary Fig. 8) .
Our findings have a number of critical implications. Notably, we provide a mechanistic basis for how different classes of cyclins can be coregulated at the protein level. Although transcriptional mechanisms have a role in regulating cyclin D and cyclin E, these mechanisms do not explain the rapid, coordinated changes in protein levels that occur. Our data demonstrate that new PARK2-based ubiquitin E3 complexes (PCFs) help mediate this coordination. Regulation of the activity of these complexes may involve a number of other processes such as post-translational modification, as is common for the fine-tuning of CRL complex activity 9, [44] [45] [46] [47] .
PARK2 can affect a number of processes that differ depending on cell type. In neural models, it can regulate processes such as cell survival and mitochondrial motility and clearance 31, 40, [48] [49] [50] [51] [52] [53] . The genetic relationship between somatic events in PARK2, CCND1, CCNE1 and CDK4 strongly implicates these genes in a common aberrant process in cancer cells-the disruption of cell cycle control. Our observations show that PARK2 can control the activity of multiple proteins that regulate cell growth. Notably, genes that reside at such nodal points, such as TP53, are frequent targets of mutation in cancer cells. PARK2 may be such a gene. We believe our study has wide implications for understanding both cell cycle regulation and oncogenesis.
METHoDS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data have been accessioned with the Gene Expression Omnibus (GEO) under series GSE50864. 
